Counterpoint: Should Benzodiazepines Be Avoided in Mechanically Ventilated Patients? No

Chest

Volumn 142, Issue 2, 2012, Pages 284-287

  Skrobik, Yoanna ^a  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE;

ARTIFICIAL VENTILATION; DRUG INTERACTION; EDITORIAL; HUMAN; INTENSIVE CARE;

BENZODIAZEPINES; CRITICAL CARE; DRUG INTERACTIONS; HUMANS; RESPIRATION, ARTIFICIAL;

MLCS; MLOWN;

EID: 84871682790     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1191     Document Type: Editorial

References (33)

1. Treggiari, MM, Romand, JA, Yanez, ND, et al. Randomized trial of light versus deep sedation on mental health after critical illness. Crit Care Med 37:9 (2009), 2527–2534.
2. Ouimet, S, Kavanagh, BP, Gottfried, SB, Skrobik, Y, Incidence, risk factors and consequences of ICU delirium. Intensive Care Med 33:1 (2007), 66–73.
3. Herridge, MS, Tansey, CM, Matté, A, et al., Canadian Critical Care Trials Group, Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med 364:14 (2011), 1293–1304.
4. Greenblatt, DJ, Harmatz, JS, Shader, RI, Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (part I). Clin Pharmacokinet 21:3 (1991), 165–177.
5. Greenblatt, DJ, Abernethy, DR, Locniskar, A, Harmatz, JS, Limjuco, RA, Shader, RI, Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 61:1 (1984), 27–35.
6. Swart, EL, Zuideveld, KP, de Jongh, J, Danhof, M, Thijs, LG, Strack van Schijndel, RM, Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients. Eur J Clin Pharmacol 62:3 (2006), 185–194.
7. Oldenhof, H, de Jong, M, Steenhoek, A, Janknegt, R, Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability?. Clin Pharmacol Ther 43:3 (1988), 263–269.
8. Greenblatt, DJ, Ehrenberg, BL, Gunderman, J, et al. Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. J Pharmacol Exp Ther 250:1 (1989), 134–140.
9. Bauer, TM, Ritz, R, Haberthür, C, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 346:8968 (1995), 145–147.
10. Ariano, RE, Kassum, DA, Aronson, KJ, Comparison of sedative recovery time after midazolam versus diazepam administration. Crit Care Med 22:9 (1994), 1492–1496.
11. Swart, EL, Zuideveld, KP, de Jongh, J, Danhof, M, Thijs, LG, Strack van Schijndel, RM, Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. Br J Clin Pharmacol 57:2 (2004), 135–145.
12. Pohlman, AS, Simpson, KP, Hall, JB, Continuous intravenous infusions of lorazepam versus midazolam for sedation during mechanical ventilatory support: a prospective, randomized study. Crit Care Med 22:8 (1994), 1241–1247.
13. Ovakim, D, Bosma, KJ, Young, GB, et al. Effect of critical illness on the pharmacokinetics and dose-response relationship of midazolam. Crit Care, 16(suppl 1), 2012, P330.
14. de Wildt, SN, de Hoog, M, Vinks, AA, van der Giesen, E, van den Anker, JN, Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. Crit Care Med 31:7 (2003), 1952–1958.
15. Gorski, JC, Hall, SD, Jones, DR, VandenBranden, M, Wrighton, SA, Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:9 (1994), 1643–1653.
16. Fukasawa, T, Suzuki, A, Otani, K, Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther 32:4 (2007), 333–341.
17. Oda, Y, Mizutani, K, Hase, I, Nakamoto, T, Hamaoka, N, Asada, A, Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro. Br J Anaesth 82:6 (1999), 900–903.
18. Saari, TI, Laine, K, Leino, K, Valtonen, M, Neuvonen, PJ, Olkkola, KT, Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 79:4 (2006), 362–370.
19. Ahonen, J, Olkkola, KT, Takala, A, Neuvonen, PJ, Interaction between fluconazole and midazolam in intensive care patients. Acta Anaesthesiol Scand 43:5 (1999), 509–514.
20. Cox, CE, Reed, SD, Govert, JA, et al. Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation. Crit Care Med 36:3 (2008), 706–714.
21. Fong, JJ, Kanji, S, Dasta, JF, Garpestad, E, Devlin, JW, Propofol associated with a shorter duration of mechanical ventilation than scheduled intermittent lorazepam: a database analysis using Project IMPACT. Ann Pharmacother 41:12 (2007), 1986–1991.
22. Hall, RI, Sandham, D, Cardinal, P, et al. Study Investigators. Propofol vs midazolam for ICU sedation: a Canadian multicenter randomized trial. Chest 119:4 (2001), 1151–1159.
23. Huey-Ling, L, Chun-Che, S, Jen-Jen, T, Shau-Ting, L, Hsing-I, C, Comparison of the effect of protocol-directed sedation with propofol vs. midazolam by nurses in intensive care: efficacy, haemodynamic stability and patient satisfaction. J Clin Nurs 17:11 (2008), 1510–1517.
24. Girard, TD, Kress, JP, Fuchs, BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet 371:9607 (2008), 126–134.
25. Skrobik, Y, Ahern, S, Leblanc, M, Marquis, F, Awissi, DK, Kavanagh, BP, Protocolized intensive care unit management of analgesia, sedation, and delirium improves analgesia and subsyndromal delirium rates. Anesth Analg 111:2 (2010), 451–463.
26. Pisani, MA, Murphy, TE, Araujo, KL, Slattum, P, Van Ness, PH, Inouye, SK, Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population. Crit Care Med 37:1 (2009), 177–183.
27. Pandharipande, P, Shintani, A, Peterson, J, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology 104:1 (2006), 21–26.
28. Riker, RR, Shehabi, Y, Bokesch, PM, et al., SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group, Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA 301:5 (2009), 489–499.
29. Shehabi, Y, Grant, P, Wolfenden, H, et al. Prevalence of delirium with dexmedetomidine compared with morphine based therapy after cardiac surgery: a randomized controlled trial (DEXmedetomidine COmpared to Morphine-DEXCOM Study). Anesthesiology 111:5 (2009), 1075–1084.
30. Kress, JP, The complex interplay between delirium, sepsis and sedation. Crit Care, 14(3), 2010, 164.
31. Awissi, DK, Bégin, C, Moisan, J, Lachaine, J, Skrobik, Y, I-SAVE study: impact of sedation, analgesia, and delirium protocols evaluated in the intensive care unit: an economic evaluation. Ann Pharmacother 46:1 (2012), 21–28.
32. Ouimet, S, Riker, R, Bergeron, N, Cossette, M, Kavanagh, B, Skrobik, Y, Subsyndromal delirium in the ICU: evidence for a disease spectrum. Intensive Care Med 33:6 (2007), 1007–1013.
33. Wunsch, H, Weighing the costs and benefits of a sedative. JAMA 307:11 (2012), 1195–1197.